Clinical trials: Vascular Patients
Angina, Stable
Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia
The purpose of this study is to determine whether a single intracoronary infusion of an adenovirus serotype 5 virus expressing the gene for human fibroblast growth factor-4 (Ad5FGF-4) is effective in improving angina-limited…
- Trial name
- AFFIRM (NCT02928094)
- Testing
- Ad5FGF-4
- Volunteers
- 160 people
- Sponsor
- Angionetics Inc.
Hypertension
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
Assess the long-term safety and tolerability of aliskiren, with the optional addition of HCTZ, in patients with essential hypertension, to ensure long term blood pressure control and protect against end organ damage.
- Trial name
- NCT00219037
- Testing
- aliskiren
- Where
- Germany
- Volunteers
- 1,955 people
- Sponsor
- Novartis
Venous Thromboembolism
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
- Trial name
- NCT03214172
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Bayer
Multiple Myeloma
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
- Trial name
- NCT04436029
- Testing
- Descartes 11
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cartesian Therapeutics
Obesity
A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program
The purpose of this study is to compare the efficacy and safety of topiramate 96mg and 192mg daily) with placebo in the treatment of obesity following an intensive non-pharmacologic weight loss program.
- Trial name
- NCT00236600
- Testing
- topiramate
- Volunteers
- 561 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypertension
Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine
PRECIOUS Study aims to evaluate the efficacy and safety of therapy with fixed-dose combination (FDC) of perindopril/amlodipine (Amlessa®) and FDC of perindopril/indapamide/amlodipine (Co-Amlessa®) on blood pressure reduction in…
- Trial name
- PRECIOUS (NCT03738761)
- Testing
- Amlessa®, Co-Amlessa®
- Where
- 34 sites in Armenia, Croatia and 5 more
- Volunteers
- 471 people
- Sponsor
- KRKA
Essential Hypertension
A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.
- Trial name
- NCT07700875
- Testing
- QR12000 Compound Tablets 75 mg, QR12000 Compound Tablets 150 mg, QR01019 potassium salt 50 mg
- Where
- China
- Volunteers
- 391 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Hypertension
Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension
The primary objective was to show that telmisartan is not inferior to metoprolol succinate in respect of the percentage change from baseline in LVMI(H) after a 6.5 months treatment period.
- Trial name
- NCT02242812
- Testing
- Telmisartan, Metoprolol succinate
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
NASH - Nonalcoholic Steatohepatitis
AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis
This is a Phase 1b multi-center, randomized, double-blind, dose-ranging, placebo-controlled, adaptive study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) of TERN-201 in patients with non-cirrhotic NASH.
- Trial name
- NCT04897594
- Testing
- TERN-201
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hypertension, Vascular Diseases
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT02439775
- Testing
- Symplicity Spyral™ multi-electrode renal denervation system
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 337 people
- Sponsor
- Medtronic Vascular
Hypertension, Diabetic Nephropathy
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
The purpose of this study is to evaluate the efficacy of valsartan, benazepril or the combination of both in reduction of microalbuminuria in Type 2 diabetic patients.
- Trial name
- NCT00171119
- Testing
- valsartan
- Where
- Switzerland
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease, Cardiovascular Diseases
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population
The primary objective of the RESOLUTE international registry is to document the safety and overall clinical performance of the Resolute Zotarolimus-Eluting Coronary Stent System in a 'real-world' patient population requiring…
- Trial name
- R-Int (NCT00752128)
- Testing
- Endeavor Resolute Zotarolimus-Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 2,349 people
- Sponsor
- Medtronic Vascular
Coronary Artery Stenosis
Coronary Non-slip Balloon Catheter in Patients With Coronary Artery Stenosis(CREST)
This is a prospective, multicenter, randomized controlled clinical investigation aiming to evaluate the safety and effectiveness of non-slip balloon catheter for the treatment of patients with coronary artery stenosis.
- Trial name
- NCT05606367
- Testing
- Non-slip Balloon Catheter of Shanghai MicroPort Rhythm, NSE Coronary Dilatation Catheter
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai MicroPort Rhythm MedTech Co., Ltd.
Coronary Artery Disease
The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.
The main objective of this study is to assess the safety and effectiveness of the sirolimus coated Bx VELOCITY stent in reducing angiographic in-stent late loss in de novo native coronary lesions as compared to the bare metal Bx…
- Trial name
- RAVEL (NCT00233805)
- Testing
- Sirolimus coated Bx Velocity™, Bare metal Bx Velocity™
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Cordis US Corp.
Ischemic Heart Disease
Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)
The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200 hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late stent thrombosis resulting in less deaths and…
- Trial name
- PROTECT (NCT00476957)
- Testing
- Stent
- Where
- Netherlands
- Volunteers
- 8,709 people
- Sponsor
- Medtronic Vascular
Hypertension
Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy
An eight week study to compare the effect of a fixed dose combination of Telmisartan 40 mg plus hydrochlorothiazide (HCTZ) 12.5 mg to Telmisartan 40 mg alone on diastolic and systolic blood pressure in patients who fail to…
- Trial name
- NCT02177500
- Testing
- Telmisartan + hydrochlorothiazide, Telmisartan
- Volunteers
- 327 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Assessment of the long-term safety and tolerability of the combination of aliskiren and valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of long-term safety and tolerability of the…
- Trial name
- NCT00386607
- Testing
- Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ)
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 601 people
- Sponsor
- Novartis
Stroke, Stroke, Acute
Evaluation of the Use of the Atalante System in Patients Presenting a Non-traumatic Hemiplegia in Acute-subacute Phase (15 Days to 6 Months).
The SPIRIT study is interventional, national, prospective, open, multicentric each patient being his/her own control. It is conducted to assess the safety and performance of the Atalante exoskeleton system in patients presenting…
- Conditions
- Stroke, Stroke, Acute, Stroke, Subacute, Robotics
- Trial name
- SPIRIT (NCT04187209)
- Testing
- Use of the Atalante exoskeleton
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Wandercraft
Multiple Myeloma
A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-5421 in patients with multiple myeloma (MM).
- Trial name
- NCT07652281
- Testing
- SHR-5421 for Injection
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cold Urticaria
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
Primary Objective: To demonstrate the efficacy of dupilumab in adult and adolescent participants with primary acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of an H1-antihistamine…
- Trial name
- NCT04681729
- Testing
- Dupilumab SAR231893, Non sedating H1-antihistamine
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.